Prolia and Dental Work: Extractions, Implants, Periodontal Surgery, and Routine Care

Prolia is denosumab at the osteoporosis dose: 60 mg by injection every six months. It is a RANKL inhibitor rather than a bisphosphonate, and that difference drives most of the dental decisions. Unlike bisphosphonates, denosumab does not accumulate in the skeleton, and its effect on bone turnover stops when the drug wears off, as the Brazilian endocrinology and stomatology societies' position paper sets out. That is why the date of the last injection matters more than the years a patient has been on treatment, and why stopping it is not an option.

This page covers the whole span of dental care. The narrow question of how long after an injection to extract is answered with its sources here, and the equivalent question for Fosamax and implants is answered here.

How big the risk is#

In clinical trials the MRONJ rate for denosumab at osteoporosis doses was 0.04%, against 0 to 0.02% for placebo and 0.017% for zoledronic acid, according to the Brazilian position paper. Its conclusion is that the risk for osteoporosis patients on any antiresorptive is real but very low, and close to the 0.001% background risk in the general population. The local risk factors the paper lists are the ones dentistry can act on: active periodontal disease, caries, pulpal and periapical infection, trauma from a removable prosthesis, and poor oral hygiene.

Why there is no drug holiday#

The Brazilian paper is explicit that a drug holiday is not recommended with denosumab, mainly because discontinuation is followed by a rapid rise in vertebral fracture risk. Position papers from several professional societies likewise do not recommend routine discontinuation of osteoporosis antiresorptives before invasive dental procedures, and no evidence-based study has shown that a bisphosphonate holiday prevents MRONJ. For denosumab, then, the lever is scheduling, not stopping. The cancer dose is a different question: for patients on denosumab for bone metastases, discontinuation around dental procedures did not change MRONJ risk in a network meta-analysis, while it carries skeletal-event risk.

Extractions: pick the window and close the socket#

Two findings set the schedule. A 2026 retrospective cohort of denosumab-treated osteoporosis patients found that every MRONJ case occurred when dentoalveolar surgery was performed within three months of the last injection, and recommends at least four months where feasible. The AAOMS 2022 position paper advises completing planned surgery three to four months after the last dose, when osteoclast inhibition is waning, and reinstituting the drug six to eight weeks after surgery. Neither of these means retaining an infected tooth until the window opens: an odontogenic infection is itself a MRONJ risk, and a necessary extraction should proceed.

Technique carries the rest of the risk. Traumatic extraction and sockets left without primary closure are more associated with MRONJ. The Brazilian paper describes atraumatic extraction, primary closure of the socket, alveoloplasty at the surgeon's discretion where it makes closure possible, antibiotic prophylaxis started before the extraction (most commonly amoxicillin with or without clavulanate) and continued until the site has healed, and follow-up until healing is complete. The timing is compared with the bisphosphonates and DOACs in the medication hold-times brief.

Implants#

The MRONJ risk after implant placement is considered comparable to the risk after extraction. Current recommendations treat oral antiresorptive therapy as no explicit contraindication to implants while advising against them in patients on intravenous antiresorptive or antiangiogenic therapy. Two points in the Brazilian paper are easy to miss. First, the implant's presence, not only its surgery, can trigger MRONJ, because peri-implant infection is a recognised risk factor; peri-implantitis in a patient on antiresorptives is a MRONJ concern, not just an implant one. Second, the consent form should record the possibility of long-term implant failure and of MRONJ at the implant site.

The pooled numbers are reassuring at osteoporosis doses. A 2025 systematic review and meta-analysis informing the International Task Force on Osteonecrosis of the Jaw found no increase in implant failure with antiresorptive exposure (relative risk 0.82, very low certainty) and a pooled MRONJ rate of 0.5% across 21 cohorts of implant recipients on antiresorptives, with bisphosphonates adding about 3 cases per 1,000 patients in the single risk-adjusted study. A 2026 systematic review specific to denosumab found only 10 small, heterogeneous studies and could not draw firm conclusions, but flagged three factors that recur: switching from a bisphosphonate to denosumab, the timing of placement relative to dosing, and peri-implantitis. Plan implants in the same injection window as extractions, follow the measures recommended for antiresorptive patients, including minimally invasive technique and avoiding bone augmentation where possible, and keep the patient on a peri-implant maintenance schedule.

Periodontal, endodontic, and orthodontic treatment#

Periodontal disease is both a reason to treat and a reason for caution. The Brazilian paper lists it as a MRONJ risk factor, and anaerobic periodontal bacteria were the main organisms found in necrotic bone from MRONJ cases, which suggests periodontal infection can initiate the process. Non-surgical periodontal therapy and maintenance should continue. Periodontal surgery is dentoalveolar surgery for planning purposes: apply the same injection-window and closure principles as an extraction.

Endodontics is the tooth-preserving alternative. A controlled clinical trial of conservative root canal treatment in patients on long-term oral bisphosphonates showed satisfactory periradicular healing, so a restorable tooth with pulpal or periapical disease is better treated than extracted. Orthodontics has not been linked to MRONJ in any study; one report described slowed tooth movement and difficulty closing spaces in three patients on oral bisphosphonates, which is a treatment-planning note rather than a contraindication.

Routine care#

Routine care is where MRONJ is prevented. The guidance summarised in a 2026 review of denosumab in dental practice consistently calls for a dental assessment and optimisation of oral health before the first dose, ongoing communication between the prescriber and the dental team, and planning any intervention around the dosing schedule. An Italian position paper for dental hygienists puts the hygienist at the centre of primary and secondary prevention: regular professional care, teaching patients to report sudden tooth loosening or an abscess promptly, distinguishing early MRONJ from a periodontal or endodontic-periodontal abscess at recall, and referring mucosal lesions or opportunistic infections. Check the fit of removable prostheses, since denture trauma is on the list of local risk factors. Restorative dentistry, hygiene visits, and radiographs need no change.

Before the first injection, and at every recall#

Ask when the last injection was and when the next is due, and write it in the chart. That single date decides the timing of any surgery. If a patient is about to start denosumab, complete extractions and any other surgery first, and let the prescriber know when the mouth is ready.